Skip to content
Study details
Enrolling now

Efficacy and Safety of Eloralintide in People With Osteoarthritis Knee Pain and Obesity or Overweight

Eli Lilly and Company
NCT IDNCT07353931ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

900

Study length

about 2.3 years

Ages

18+

Locations

34 sites in AL, AZ, CA +12

About this study

This trial is testing a treatment called Eloralintide to see if it helps people with osteoarthritis knee pain who are also overweight or obese. The trial will last about 75 weeks, including screening.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Eloralintide
  • 2.Take Placebo
PhasePhase 3
Primary goalChange from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low6%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score, Percent Change from Baseline in Body Weight

Secondary: Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Pain, Change from Baseline WOMAC Pain Subscale Score, Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) Score, Change from Baseline in Body Mass Index (BMI), Change from Baseline in Distance Walked During the 6-Minute Walk Test, Change from Baseline in Health Status EQ-5D-5L Health State Utility, Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score, Change from Baseline in Short Form-36 (SF-36 v2) Acute Form Physical Functioning Domain Score

Body systems

Endocrinology, Musculoskeletal